These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36984479)

  • 1. Optimization of Therapy and the Risk of Probiotic Use during Antibiotherapy in Septic Critically Ill Patients: A Narrative Review.
    Onofrei MI; Ghiciuc CM; Luca CM; Postolache P; Sapaniuc C; Enache Leonte G; Rosu FM
    Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
    Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
    Gatti M; Pea F
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
    Gatti M; Pea F
    Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.
    Gatti M; Cojutti PG; Bartoletti M; Tonetti T; Bianchini A; Ramirez S; Pizzilli G; Ambretti S; Giannella M; Mancini R; Siniscalchi A; Viale P; Pea F
    Crit Care; 2022 Jun; 26(1):178. PubMed ID: 35701812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
    Kalaria SN; Gopalakrishnan M; Heil EL
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
    J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes.
    Joynt GM; Ling L; Wong WT; Lipman J
    Expert Rev Clin Pharmacol; 2023; 16(8):703-714. PubMed ID: 36942827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.